TABLE OF CONTENTS
Volume 6, Issue 2 (February 2009)
Original Articles |
US Case Reports |
EU Case Reports |
US Legal and Regulatory Update |
EU Legal and Regulatory Update
Editorial
The generic industry is changing and will require new global strategies and policies FREE
Maria Fabiana Jorge Managing Editor
J Generic Med 6: 97-98; doi:10.1057/jgm.2009.3
Original Articles
World Intellectual Property Organization Development Agenda
Alberto J Dumont and Inés Gabriela Fastame
J Generic Med 6: 99-110; doi:10.1057/jgm.2009.5
Biosimilar EPO: The reasons to be confident
Elisabeth Berthet-Maillols
J Generic Med 6: 111-128; doi:10.1057/jgm.2009.1
Developing the Japanese generic medicines market: What can we learn from Europe?
Steven Simoens
J Generic Med 6: 129-135; doi:10.1057/jgm.2009.4
The generic pharmaceutical market in South Africa: At the crossroads?
National Association of Pharmaceutical Manufacturers (NAPM)
J Generic Med 6: 137-144; doi:10.1057/jgm.2009.2
US Case Reports
Abbott v. Sandoz: If at first you don't succeed, try, try again
Frederick H Rein and Joseph B Crystal
J Generic Med 6: 145-156; advance online publication, December 2, 2008; doi:10.1057/jgm.2008.34
EU Case Reports
High court finds patent for a compound selected from a known class valid, without reference to 'selection invention' principles; High Court confirms that enantiomers are entitled to separate SPC protection from their racemate; Court assesses compensation payable to a generic company unfairly kept off the market
Michael Burdon and Rebecca Singleton
J Generic Med 6: 157-166; doi:10.1057/jgm.2008.36
US Legal and Regulatory Update
Recent cases highlight shortcomings and inconsistencies in the law: In re Ciprofloxacin; Celgene v. KV and SB Pharmco v. Mutual
Fahd K Majiduddin and Paul A Braier
J Generic Med 6: 167-175; advance online publication, January 13, 2009; doi:10.1057/jgm.2008.37
